Gilead Sciences (NASDAQ: GILD) and Merck (NYSE: MRK) announced that their investigational once-weekly oral HIV treatment combining islatravir and lenacapavir ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE